Effect of Kutaki (Picrorhiza Kurroa Royle Ex Benth) on Dyslipidemia
Life Sciences -Ayurveda
DOI:
https://doi.org/10.22376/ijlpr.2023.13.5.L146-L155Keywords:
Dyslipidemia, Kutaki, Medoroga, Medodushti, Picrorhiza.Abstract
Dyslipidemia is a lifestyle disorder related to a metabolic disorder of lipoprotein metabolism. It is mainly characterizedby raised (TCH) total cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride (TG) levels, and a fall in the high-densitylipoprotein (HDL) cholesterol levels. It is the key contributing cause of atherosclerosis, coronary artery ailment, andcerebrovascular disease. It can be equated with medodushti and included under Santarpanjanya vyadhi as “Medoroga. This studyassesses the effect of Kutaki (Picrorhiza kurroa Royle ex Benth) on Dyslipidemia. A total of 30 patients with Dyslipidemia weretreated with Kutaki tablets 500 mg twice a day before meals with lukewarm water for 60 days. They were assessed for Lipid levels,Fasting glucose level, AST, ALT, S.Creatinine, and Serum Urea on days 0, 30, and 60. Significant improvement was observed in allparameters after the completion of treatment. Tikta Rasa (bitter taste), Ushna Virya (hot potency), Agnideepan, Pachana, and Lekhanaproperties of Kutaki help break Samprapti. Active ingredients of Kutaki possess Hypolipidemic and choleretic properties, whichhelp correct Lipid levels. Hepatoprotective and nephroprotective properties help in maintaining liver and kidney functionsnormally. It helps in improving deranged Agni and constipation. Kutaki can be useful in treating Dyslipidemia with any side effects.
References
API textbook of medicine. 10th ed, Jaypee Brothers Medical publishers, Published 2015; pp 2872; pg.1690.
Davis CE, Rifkind BM, Brenner H, Gordon DJ. A single cholesterol measurement underestimates the risk of coronary heart disease. An empirical example from the lipid research clinics mortality follow-up study. JAMA. 1990;264(23):3044-6. PMID 2243433 [Cross Ref].
Gulati S, Misra A, Pandey RM. Effects of 3 g of soluble fiber from oats on lipid levels of Asian Indians - a randomized controlled, parallel arm study. Lipids Health Dis. 2017;16(1):71. doi: 10.1186/s12944-017-0460-3, PMID 28376899.
WHO. Cardiovascular Disease, ‖ Fact sheet no. 317. Geneva, Switzerland: WHO; 2009. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/print.html.
Madhavakara, Madhava Nidana with Madhukosha commentary of Vijaya rakshita and Shrikantadatta, Medoroga Nidanam, published by Varanaseya Sanskrit Samsthana; Varanasi. 1993. Pg.No;28.
Agnivesha CS, Revised by Charaka and Drdhabala. Ayurveda Dipika Commentry of Chakrapani Datta Vaidya Jadavji Trikamji A, editor. Varanasi: Chowkhamba Krishnadas Academy [reprint]; 2010,suthrasthana [Chapter]- 21. p. 116, P.-738.
Sircar NN, DASEMANI DRUGS P-TOF. Pharmaco – therapeutics of dasemani drugs. Anc Sci Life. 1984 Jan;3(3):132-5. PMID 22557394.
Braunwald E, Fanci AS, Hauser SL, Kasper DL, Longo DL, Jameson JL, editors. Harrison TR. Harrison’s Principles of Internal Medicines, 19th. international ed. Vol. II. New York: McGraw-Hill Medical Publishing Division, pg no. (2447).
Shetty SN, Mengi S, Vaidya R, Vaidya AD. A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. J Ayurveda Integr Med. 2010 Jul;1(3):203-10. doi: 10.4103/0975-9476.72622, PMID 21547049.
Lee HS, Yoo CB, Ku SK. Hypolipemic effect of water extracts of Picrorhizakurroa in high fat diet treated mouse. Fitoterapia. 2006;77(7-8):579-84. doi: 10.1016/j.fitote.2006.09.004, PMID 17056204.
Guo ZJ, Hou FF, Liu SX, Tian JW, Zhang WR, Xie D et al. Picrorhiza scrophularo flora. Int J Cardiol. 2009;136(3):315-24. doi: 10.1016/j.ijcard.2008.12.102, PMID 19178960.
Anonymous. Picrorziza kurroa. Indian herbal pharmacopoeia. RRL Jammu tawi and Indian Drug Manufacturers’ Association, Mumbai. 1998;1:106-13.
Vrat SP, Priyanighantuh. Along with the author’s Hindi commentary entitled ’PADMA’, Chaukhamba Surbharti Prakashan,Varanasi,2004. p. 104-5.
Gogte MV. Ayurvedic pharmacology and therapeutic uses of medicinal plants (DravyagunaVignyan). New Delhi: Chaukhambha publication; 2009. p. 325-7.
Sharma PV. Introduction of Dravyaguna- Indian pharmacology. 15th ed, Chaukhambha Orientalia. Varanasi; 1976. p. 148-50.
Sultan P, Jan A, Pervaiz Q. Phytochemical studies for quantitative estimation of iridoid glycosides in Picrorhiza kurroa Royle. Bot Stud. 2016 Dec;57(1):7. doi: 10.1186/s40529-016-0121-2. PMID 28597416, PMCID PMC5430581.
Prakash V, Kumari A, Kaur H, Kumar M, Gupta S, Bala R. Chemical constituents and biological activities of genus picrorhiza: an update. Indian J Pharm Sci. 2020 Apr 10;82(4):562-77. doi: 10.36468/pharmaceutical-sciences.682.
Anonymous. The ayurvedic pharmacopoeia of India. Part-I, Government of India Ministry of Health and Family welfare Department of Ayush. 2007;2:9193.
Shailaja S, Samhita S. ”Jivanprada” Hindi commentary, Purva Khanda, Second Adhyaya, Choukhamba Orientalia, Varanasi 2005,pg. No. 15.
Krishna B et al. Single dose oral toxicity study of Picrorhizakurroa rhizome extract in Wistar rats Fundamental Toxicological Sciences. Fundam Toxicol Sci. 2016;3(1):9-12.
NCEP. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421). doi: 10.1161/circ.106.25.3143, PMID 12485966.
Bhavamishra BN. ”Vidyotini commentary” by Pandit Brahma Shankar Mishra, part 2. Chaukhambha Sanskrit bhavan. 11th ed, madhyakhand 39/15 , pp-836, pg 407.
Anonymous. The ayurvedic pharmacopoeia of India. Part-I, Government of India Ministry of Health and Family welfare Department of Ayush. 2007;2:91-3.
Gogte MV. Ayurvedic pharmacology and therapeutic uses of medicinal plants (DravyagunaVignyan). New Delhi: Chaukhambha publication; 2009. p. 325-7.
Wang D, Feng B, Yang C. Chemical constituents from Picrorhiza scrophularii flora. Acta Metall Sin. 1993;15(01):1-3.
Singh B, Rastogi RP. Chemical examination of Picrorhiza kurroa Part VI: Reinvestigation of kutkin. Indian J Chem. 1972;10:29-31.
Koolman AH, Bloks VW, Oosterveer MH, Jonas I, Kuipers F, Sauer PJ, et al. Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition. Int J Obes (Lond). 2010;34(2):374-84. doi: 10.1038/ijo.2009.219, PMID 19844210.
Pandey BR, Verma P. Therapeutic potential of Picrorrhiza kurroa in prevention and treatment of hepatic disorders: an overview. Int J Sci Innov Res. 2013;1(1):1-3.
Chander R, Singh K, Visen PK, Kapoor NK, Dhawan BN. Picroliv prevents oxidation in serum lipoprotein lipids of Mastomys coucha infected with Plasmodium berghei. Indian J Exp Biol. 1998;36(4):371-4. PMID 9717447.
Dwivedi Y, Rastogi R, Garg NK, Dhawan BN. Picroliv and its components kutkoside and picroside I protect liver against galactosamine‐induced damage in rats. Pharmacol Toxicol. 1992 Nov;71(5):383-7. doi: 10.1111/j.1600-0773.1992.tb00566.x, PMID 1333078.
Siddiqi A, Nazneen Z, Haqnawaz, Alam SS, Tariq S. Mechanism of nephroprotection by Picrorhiza Kurroa. J Ayub Med Coll Abbottabad. 2018 Apr-Jun;30(2):184-6. PMID 29938416.
Opoku S, Gan Y, Fu W, Chen D, Addo-Yobo E, Trofimovitch D et al. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019;19(1):1500. doi: 10.1186/s12889-019-7827-5, PMID 31711454.
Husain GM, Rai R, Rai G, Singh HB, Thakur AK, Kumar V. Potential mechanism of anti-diabetic activity of Picrorhiza kurroa. CELLMED. 2014;4(4):27-1.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr.Sadhana Misar Wajpeyi, Dr. Ketki Wajpeyi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.